← back
Ep 203 Ask Money Purse - Wockhardt Innovation Opportunity
Original: Ep-203 #AskMoneyPurse
Takeaway
Wockhardt's novel antibiotic pipeline (Zaynich + Nafithromycin) represents a massive multi-year re-rating opportunity if Phase 3 approvals come through.
Summary
- Deep dive on Wockhardt: most Indian pharma cuts R&D to boost margins but Wockhardt is one of few investing in true innovation
- Lead drug Zaynich (WCK 5222) targets gram-negative infections (UTI, abdominal, bloodstream); Phase 3 nearly complete with 100% success on 45 compassionate-use patients; $25bn global market
- Second drug Miqnaf/Nafithromycin (WCK 5873) is azithromycin alternative for pneumonia; CDSCO approval received; targeting Rs 500-600 cr revenue in 2-3 years, 60-70% market share in 4-5 years
- Antibiotic resistance is rising rapidly - 8 million deaths/year projected by 2050 globally - making these novel antibiotics strategically valuable; 15-year competition-free window if approved
pharmaWockhardtinnovation
Original description
Book Your High Return FD with Stable Money App: https://stablemoney.onelink.me/rkWL/u6g3tyyz TELEGRAM: https://telegram.openinapp.co/money-purse You can learn Basics of Stock markets for beginners, How to do Fundamental Analysis of a stock or any company, Expert Interviews, Financial Planning, Tax planning , Daily Stock Market News and many more for free in our channel Get free Knowledge and learn how to be a pro in Stock Market Investments and your Personal Finance. Stay In Touch👇 Also connect with us on👇 📷Instagram: https://www.instagram.com/moneypurseadv/ 🕊Twitter: https://twitter.com/Moneypurseadv 📱Facebook: https://www.facebook.com/moneypurseadv/ Thanks for watching.. Team Money Purse 00:00 Must watch Pharma Stock 10:10 Diversify the Investment 13:05 Focus this Liquor Stocks 15:15 Expecting 12% Return from Mutual Funds 17:19 Sunday Funday 17:39 Career Guidance for IT Employee 22:57 Alpha generation in Index funds? 26:20 ITC Investment in this Rs.18 Hotel stock 27:40 Financial planning for 20Years old 30:51 Monthly income from ETFs?